Hikma Pharmaceuticals cuts full-year generics revenue forecast
Monday, November 02, 2015
Drugmaker Hikma Pharmaceuticals Plc said trading in its generics unit was below its expectations due to slower-than-anticipated growth in the sales of its gout drug and cut its full-year revenue forecast for the unit.
Hikma now expects revenue in the generics business to be $150 million, down from its earlier range of $175 million to $200 million.
The Jordanian company, which makes and markets branded and non-branded generic and injectable drugs, also said it expected 2015 adjusted operating margins for the unit to be in the high twenties.
reuters.com
